Intercellular Transfer of CD155 Mediated by Melanoma Extracellular Vesicles Downregulates DNAM-1 Expression on NK Cells.
9 affiliations
- 1Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
- 2School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4001, Australia.
- 3JC STEM Lab of Personalised Cancer Medicine, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
- 4Department of Otorhinolaryngology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
- 5Department of Bioconvergence Science, Graduate School, CHA University, Seongnam 13488, Republic of Korea.
- 6Department of Paediatric Haematology, Oncology and Immunodeficiency, Justus-Liebig-University Giessen, 35392 Giessen, Germany.
- 7Department of Medicinal Biosciences and Bioengineering, Bioengineering, Inha University, Incheon 22212, Republic of Korea.
- 8Department of Biological Sciences and Bioengineering, Inha University, Incheon 22212, Republic of Korea.
- 9Institute for Experimental Oncology, University Hospital Bonn, 53127 Bonn, Germany.
Abstract
Melanoma is a highly immunogenic cancer, and immunotherapy is the first-line treatment for patients with advanced disease. However, CD155 overexpression in melanoma has been associated with resistance to immunotherapy. Whether CD155 can be transferred from tumour cells via extracellular vesicles (EVs), and how this transfer affects immune responses in melanoma, remains unclear. To investigate melanoma cell transfer of CD155 in vivo, B16F10-WT and B16F10-CD155KO melanoma cells were subcutaneously injected into CD155-/- mice. We show that CD155 is transferred from melanoma cells to several immune cell populations infiltrating the tumour, at least partly through EV secretion and uptake. DNAM-1 expression was significantly reduced on natural killer (NK) cells in B16F10-WT tumours compared with B16F10-CD155KO tumours. We also found that CD155 was enclosed and enriched in different melanoma EV subtypes. Finally, incubation of NK cells with CD155⁺ melanoma EVs increased cellular CD155 levels and led to downregulation of DNAM-1. In summary, melanoma-derived CD155 is enriched in melanoma EVs and transferred to immune cells, especially NK cells. Moreover, cancer-derived CD155⁺ EVs increase CD155 expression on NK cells and are associated with reduced DNAM-1 expression.
Related
- Multifaceted Role of Extracellular Vesicles: Intercellular Messengers to Therapeutic Applications: A Narrative Review
- Genome instability triggers intercellular DNA transfer between human cells
- Natural killer cell-derived extracellular vesicles in cancer: mediators of intercellular communication and tumor immune signaling
- Feed-based delivery of plasmid DNA using milk-derived extracellular vesicle-polyethylenimine complexes enables hepatic transgene expression in goldfish
- A contact-mediated transfer mechanism directs in cis localization and spread of Xist RNA
BibTeX
@article{wu2026intercellular,
title = {{Intercellular Transfer of CD155 Mediated by Melanoma Extracellular Vesicles Downregulates DNAM-1 Expression on NK Cells.}},
author = {Li-Ying Wu and Luize Goncalves Lima and Sunyoung Ham and Mina Lim and Su-Ho Park and Yue Su and Xuanxuan Li and Edna Pei Zhi Chai and Matthias Braun and Yong-Soo Choi and Tobias Bald and Andreas Möller},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198699},
url = {https://europepmc.org/article/MED/42883943},
note = {CC BY},
}
RIS
TY - JOUR
TI - Intercellular Transfer of CD155 Mediated by Melanoma Extracellular Vesicles Downregulates DNAM-1 Expression on NK Cells.
AU - Li-Ying Wu
AU - Luize Goncalves Lima
AU - Sunyoung Ham
AU - Mina Lim
AU - Su-Ho Park
AU - Yue Su
AU - Xuanxuan Li
AU - Edna Pei Zhi Chai
AU - Matthias Braun
AU - Yong-Soo Choi
AU - Tobias Bald
AU - Andreas Möller
PY - 2026
DA - 2026/09/29
JO - International journal of molecular sciences
DO - 10.3390/ijms27198699
UR - https://europepmc.org/article/MED/42883943
AB - Melanoma is a highly immunogenic cancer, and immunotherapy is the first-line treatment for patients with advanced disease. However, CD155 overexpression in melanoma has been associated with resistance to immunotherapy. Whether CD155 can be transferred from tumour cells via extracellular vesicles (EVs), and how this transfer affects immune responses in melanoma, remains unclear. To investigate melanoma cell transfer of CD155 in vivo, B16F10-WT and B16F10-CD155KO melanoma cells were subcutaneously injected into CD155-/- mice. We show that CD155 is transferred from melanoma cells to several immune cell populations infiltrating the tumour, at least partly through EV secretion and uptake. DNAM-1 expression was significantly reduced on natural killer (NK) cells in B16F10-WT tumours compared with B16F10-CD155KO tumours. We also found that CD155 was enclosed and enriched in different melanoma EV subtypes. Finally, incubation of NK cells with CD155⁺ melanoma EVs increased cellular CD155 levels and led to downregulation of DNAM-1. In summary, melanoma-derived CD155 is enriched in melanoma EVs and transferred to immune cells, especially NK cells. Moreover, cancer-derived CD155⁺ EVs increase CD155 expression on NK cells and are associated with reduced DNAM-1 expression.
SN - 1422-0067
ER -